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Background: Tumor necrosis factor-alpha (TNF-α) is elevated early in injured brain after traumatic brain injury (TBI),
in humans and in animals. Etanercept (a TNF-α antagonist with anti-inflammatory effects) attenuates TBI in rats by
reducing both microglial and astrocytic activation and increased serum levels of TNF-α. However, it is not known
whether etanercept improves outcomes of TBI by attenuating microglia-associated, astrocytes-associated, and/or
neurons-associated TNF-α expression in ischemic brain. A well clinically relevant rat model, where a lateral fluid
percussion is combined with systemic administration of etanercept immediately after TBI, was used. The
neurological severity score and motor function was measured on all rats preinjury and on day 3 after etanercept
administration. At the same time, the neuronal and glial production of TNF-α was measured by
Immunofluorescence staining. In addition, TNFα contents of ischemic cerebral homogenates was measured using
commercial enzyme-linked immunosorbent assay kits.
Results: In addition to inducing brain ischemia as well as neurological and motor deficits, TBI caused significantly
higher numbers of microglia-TNF-α double positive cells, but not neurons-TNF-α or astrocytes-TNF-α double
positive cells in the injured brain areas than did the sham operated controls, when evaluated 3 days after TBI. The
TBI-induced cerebral ischemia, neurological motor deficits, and increased numbers of microglia-TNF-α double
positive cells and increased TNF-α levels in the injured brain were all significantly attenuated by etanercept therapy.
Conclusion: This finding indicates that early microglia overproduction of TNF-α in the injured brain region after TBI
contributes to cerebral ischemia and neurological motor deficits, which can be attenuated by etanercept therapy.
Studies in this model could provide insight into the mechanisms underlying neurological motor disturbance in
brain-injured patients.
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Tumor necrosis factor-alpha (TNF-α) is elevated in both
the serum and cerebrospinal fluid of humans after trau-
matic brain injury (TBI) [1,2]. It is also elevated 1 to 4
hours after injury in clinically relevant models of TBI
such as lateral fluid-percussion injury (FPI) [3-5]. The* Correspondence: jessica.cpchang@gmail.com
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reproduction in any medium, provided the oroverproduction of TNF-α caused by TBI can be signifi-
cantly attenuated by blockade of TNF-α synthesis or ac-
tivity [6-8]. However, the cellular sources of this early
elevation of TNF-α remain unclear. Evidence has indi-
cated that TNF-α is predominantly expressed by neu-
rons [7] or microglia [9,10] in the injured brain.
Etanercept is a TNF antagonist with anti-inflammatory
effects. Systemic administration at the dosage of 5 mg/kg
of body weight improves outcomes of TBI in rats by redu-
cing microglial and astrocytic activation and activated in-
flammation (e.g., increased serum levels of TNF-α) [8].
Again, it is not known whether etanercept improvesd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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astrocytes-associated and/or neurons-associated TNF-α
expression in ischemic brain.
We explored these two questions by studying the
interrelationship between the activation of microglia-
TNF-α, astrocyte-TNF-α, and neuron-TNF-α double la-
beling cells in the ischemic brain areas and the develop-
ment of cerebral ischemia and neurological and motor
dysfunction as well as the attenuating of cerebral ische-
mia and neurological and motor dysfunction by
etanercept therapy after TBI.
Methods
Animals
Male Sprague–Dawley rats (280–300 g), obtained from
the Animal Resource Center of the Taiwan National Sci-
ence Council, were housed four per group at an ambient
temperature of 22 ± 1°C with a 12-h light–dark cycle.
Pelleted rat chow and tap water were available ad
libitum. All protocols, designed to minimize discomfort
in the animals during surgery and in the recovery period,
were approved by the Institutional Animal Care and Use
Committee of Southern Taiwan University of Science
and Technology.
Surgery
The rats were anesthetized with sodium pentobarbital
(25 mg/kg, intraperitoneally [i.p.]; Sigma Chemical, St.
Louis, MO, USA) and a mixture containing ketamine
(4.4 mg/ kg, intramuscularly [i.m.]; Nankuang Pharmaceut-
ical, Tainan, Taiwan), atropine (0.02633 mg/kg, [i.m.];
Sintong Chemical, Taoyuan City, Taiwan), and xylazine
(6.77 mg/kg, [i.m.]) (Bayer AG, Leverkusen, Germany).
Both the femoral artery and vein on the right side were
cannulated with PE50 polyethylene tubing to monitor
blood pressure and analyze blood gas respectively. After
cannulation, the wound was sutured and the rats were
placed in a stereotaxic frame. Each rat’s scalp was sagittally
incised, and then the rat was subjected to a FPI [11,12].
Prior to FPI, a 4.8-mm circular craniotomy was performed
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Goat-IgG (DyLight 488) Goat IgG donkey3.0 mm to the right of the central suture. A modified
Luer-Lock connector (trauma cannula) (2.6 mm inner
diameter) was secured into the craniotomy with cyano-
acrylate adhesive and dental acrylic. Subsequently, the FPI
was induced by a pressure (severe intensity: amplitude of
2.2 atm ospheres) delivered by a fluid percussion device
(Virginia Commonwealth University Biochemical Engineer-
ing, Richmond, VA, USA). The rat was removed from the
device with the acrylic removed, and the incision sutured.
Each injured and sham-injured animal for the FPI model
was housed individually and closely evaluated for behavioral
recovery immediately after the FPI. During the surgical pro-
cedure, mean arterial pressure, heart rate, and core
temperature were continuously monitored for indicating
depth of anesthesia.Experimental procedures
The rats (n=96) were randomly allocated into the following
groups: 1) FPI+saline control group (n=32): rats were
subjected to FPI plus a dose of normal saline (1 ml/kg body
weight [i.p.]) once every 12 h for 3 consecutive days [8]; 2)
FPI+etanercept group (n = 32): this group was subjected to
FPI plus etanercept (5 mg/kg body weight [i.p.]) once per
12 h for 3 consecutive days; and 3) untreated Sham group
(n = 32): rats were subjected to the same surgical proce-
dures as the other two groups, but were not given a FPI.
The injection volume was the same for both saline and
etanercept groups. The sham-group was untreated.
In experiment 1, etanercept (5 mg/kg [i.p.]) (n=8) or sa-
line (1 ml/kg [i.p.]) (n=8) was randomly administrated im-
mediately after FPI, and their effects on neurological
motor performance were assessed preinjury and on 4 days
post-FPI. Another 8 untreated sham-operated rats were
used as controls. Etanercept (ENBREL™ Wyeth Labora-
tories, Hampshire, UK) was reconstituted with normal sa-
line according to the manufacturer’s instructions.
In experiment 2, three days after FPI, immediately fol-
lowing the neurological motor tests, all the rats used in
experimental 1 were killed 3 days after FPI for brain
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saline (1 ml/kg [i.p.] (n=8) was randomly given to each
rat immediately after FPI once every 12 h for 3 con-
secutive days, and the effect on the number of the co-
localization of TNF-α and microglia specific marker
cells, TNF-α and neurons specific marker cells, and
TNF-α and astrocyte specific marker cells in theFigure 1 Etancercept attenuated FPI-induced increased neurological s
increased brain ischemic volume (C). *The FPI+saline group (▤; n=8) sh
maximal angle (P<0.05), and a significant increase in brain ischemic volume
3 days post-FPI. +The FPI+etanercept group (▩; n=8) showed a significant
(P<0.05), and a significant decrease in brain ischemia volume (P<0.05) comcortex, white matter, hippocampus, or hypothalamus
was determined. Untreated sham group, FPI+saline
group, and FPI-etanercept group were killed 72 h
post-FPI (n=8 for each group) for immunohistological
evaluation.
In experiment 4, untreated sham group (n=8), FPI+sa-
line group (n=8), and FPI+etanercept group (n=8)everity scores (NSS) (A), decreased motor performance (B), and
owed a significant increase in NSS (P<0.01), a significant decrease in
(P<0.05) compared with the untreated sham-operated group (■)
decrease in NSS (P<0.05), a significant increase in maximal angle
pared with the FPI+saline group (▤; n=8).
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TNF-α protein level in ischemic brains.
Neurological function evaluation
Acute neurological injury was assessed in all rats on the
day prior to and on 3 days after surgery using a neuro-
logical severity score (NSS) [13]. NSS is a composite of
the motor (muscle status, abnormal movement), sensory
(visual, tactile and proprioceptive) and reflex tests. One
point was given for failure to perform a task. Thus, the
higher score, the more severe is injury, with a maximum
of 14 points. The NSS was measured on all rats pre in-
jury and on day 3 after etanercept administration.
The inclined plane was used to measure limb strength
[14]. The rat was placed, facing right and then left, per-
pendicular to the slope of a 20×20-cm ruffed surface of an
inclined plane starting at an angle of 55°. The angle was
increased or decreased in 5° increments to determine the
maximal angle at which a rat could hold to the plane. TheFigure 2 Etanercept decreased FPI-induced increases in the number o
ischemic cortical regions. Representative panel staining 72 h after sham o
FPI+saline rat and (C) a FPI+etanercept rat. (D) The FPI+saline group (▤) sh
microglia and TNF-α specific marker cells in the ischemic cortex 72 h after
FPI+etanercept group showed a significant decrease in the number of co-l
with the FPI+saline group (▤) (+P < 0.01). Each column and bar is the meadata for each day were the mean of the left- and right-side
maximal angles. All behavioral tests were examined and
independently scored by two observers who were unaware
of what treatment the rats had been given. These scores
were averaged to arrive at one score for each rat for the
behavioral session. The rats were tested pre injury and on
day 3 after etanercept administration.
TNF-α content of ischemic cerebral homogenate
Cerebral hemispheres were quickly dissected free and
kept on ice in physiological salt solution (mM: NaCl
119; KCl 4.7; MgSO4 1.17; KH2PO4 1.18; NaHCO3 25;
EDTA 0.026; and CaCl2 2.5) containing 5 mM glucose.
Segments of cerebral cortex (75 mg i.e., approximately
the weight of each cerebral hemisphere) were weighted,
cut into small pieces, dispersed by aspiration into a pip-
ette and suspended in 1 ml of physiological salt solution
in a test tube. Samples were kept on wet ice for 20 min
before use. The homogenates were centrifuged at 7,500f co-localization of microglia and TNF-α specific marker cells in
peration or FPI, respectively for (A) a sham operation rat, (B) a
owed a significant increase in the number of co-localization of
FPI compared with the sham controls (■) (*P < 0.01). The
ocalization of microglia and TNF-α specific marker cells (▩) compared
n ± SD of eight rats per group.
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for measuring TNF-α concentrations. TNF-α concentra-
tions were measured using commercial enzyme-linked
immunosorbent assay (ELISA) kits (Biosource Inter-
national Inc. Boshide Company, Wuhan, China) and fol-
lowing the manufacturer’s instructions. The minimum
detectable concentrations of TNF-α were 1.1 pg/ml.
There was no cross-reactivity reported with other cyto-
kines. All samples were assayed is duplicate.Cerebral ischemia assay
The triphenyltetrazolium chloride (TTC) staining proce-
dures are described elsewhere [15]. Three days after they
had undergone FPI, all the rats were deeply anesthetized
(sodium pentobarbital, 100 mg/kg [i.p.]) and then perfused
intracardially with saline. Their brain tissue was then re-
moved, immersed in cold saline for 5 min, and sliced into
2.0-mm sections with a tissue slicer. The brain slices wereFigure 3 Etanercept decreased FPI-induced increases in the number o
ischemic white matter regions. Representative panel staining 72 h after F
(C) a FPI+etanercept rat. (D) The FPI+saline group (▤) showed a significan
specific marker cells in the ischemic white matter 72 h after FPI compared
showed a significant decrease in the number of co-localization of microglia
compared with the FPI+saline group (▤) (+P < 0.01). Each column and barincubated in 2% TTC dissolved in phosphate buffer saline
(PBS) for 30 min at 37°C and then transferred to 5% for-
maldehyde solution for fixation. The volume of ischemia,
revealed by negative TTC stains that indicated
dehydrogenase-deficient tissue, was measured in each slice
and summed using computerized planimetry (PC-based
Image Tools Software). The volume of ischemia was cal-
culated as 2 mm (thickness of the slice)×[sum of the ische-
mia area in all brain slices (mm)2].Immunohistological determination
Serial 50-μm sections corresponding to coronal coordi-
nates 0.8 mm to 5.3 mm posterior to the bregma were
incubated in 2 mol/L HCL for 30 min, rinsed in
0.1 mol/L boric acid (pH 8.5) for 3 min at room
temperature and then incubated with primary antibodies
in phosphate-buffered saline (PBS) containing 0.5%
normal bovine serum at 4°C overnight; secondaryf co-localization of microglia and TNF-α specific marker cells in
PI, respectively, for (A) a sham operation rat, (B) a FPI+saline rat and
t increase in the number of co-localization of microglia and TNF-α
with the Sham controls (■) (*P < 0.01). The FPI+etanercept group (▩)
and TNF-α specific marker cells in the ischemic white matter
is the mean ± SD of eight rats per group.
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antibodies therein were, sequentially, mouse monoclonal
anti-NeuN (Abcan, 1:200), mouse monoclonal anti-
GFAP antibody (Abcam, 1:200), mouse monoclonal
anti-Iba-1 antibody (Abcam, 1:200), goat polyclonal anti-
TNF-α antibody (Santa Cruz, 1:50), DyLight 488-
conjugated donkey-anti-goat IgG antibody (Abcam,
1:400), and Alexa Fluro 568-conjugated donkey anti-mouse
IgG antibody (Invitrogen, 1:400). The sections were
coverslipped with the mounting medium (fluorescent
mounting medium; Dako). The labeled cells were calcu-
lated in 5 coronal sections from each rat and expressed
as the mean number of cells per section. For negative
controls sections, all the procedures were without the
primary antibody. Primary and secondary antibodies for
multiple-staining are listed in Table 1.
Images of the fluorescent immunohistochemistry for
immune cells were captured at 100x magnification usingFigure 4 Etanercept decreased FPI-induced increases in the number o
ischemic hippocampal regions. The FPI+saline group (▤) showed a sign
TNF-α specific marker cells cells in the ischemic hippocampus 72 h after FP
panel staining 72 h after FPI, respectively, for (A) a sham operation rat, (B)
group (▩) showed a significant decrease in the number of co-localization
compared with the FPI+saline group (▤) (+P < 0.01). Each column and bara fluorescence microscope system (Zeiss Axiovision;
Zeiss Gmbh, Göttingen, Germany), and images from
bregma −0.8, -1.5, -2.5, -3.0, and −3.5 mm from each ani-
mal were evaluated. In each image, immune-positive cells
showing staining with a cellular morphology and above
background level were manually and exhaustively counted
using the Axiovision image analysis software (Zeiss
Gmbh), All cell counts were performed by an investigator
(C. P.C.) blinded to the treatment status of each animal.
Statistical analysis
The data are presented as mean ± standard deviation
(SD). A repeated measures analysis of variance was used
to test the treatment-by-time interactions and the effect
of treatment over time on each score. Duncan’s multiple
range test was used for post hoc multiple comparisons
among means. Analyses for all behavioral variables used
Student’s unpaired t-test to compare variables betweenf co-localization of microglia and TNF-α specific marker cells in
ificant increase of the numbers of co-localization of microglia and
I compared with the Sham controls (■) (*P < 0.01). Representative
a FPI+saline rat and (C) a FPI+etanercept rat. (D) The FPI+etanercept
of microglia and TNF-α specific marker cells in ischemic hippocampus
is the mean ± SD of eight rats per group.
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appropriate, to determine post-hoc significance at indi-
vidual time point. Data was analyzed using Statistica,
SoftwareW and, in all cases, statistical significance was
set at P<0.05.Results
Acute effects of FPI
The average intensity of the fluid pulse delivered to ani-
mals in the injured group was 2.24±0.05 atm (mean
±SEM). Immediately following this impact, all rats experi-
enced a period of apnea (lasting approximately 25 sec),
hypertension (approximately up to ~140 mmHg and last-
ing ~25 sec), and tachycardia (~390 beats/min and lasting
more than 120 minutes). Sham-injured animals showed
no apnea, hypertension, or tachycardia. There was no dif-
ference between 2 treatment groups.Figure 5 Etanercept decreased FPI-induced increases in the number o
ischemic hypothalamic regions. Representative panel staining at 72 h aft
and (C) a FPI+etanercept rat (D) The TBI+saline group (▤) showed a signif
specific marker cells cells in the ischemic hypothalamus 72 h after TBI com
(▩ ) showed a significant decrease of the numbers of co-localization of mi
group (▤) (+P < 0.01). Each column and bar is the mean ± SD of eight ratsFPI caused neurological and motor dysfunction, which
etanercept attenuated
Three days after the rats had been subjected to FPI,
behavioral tests revealed that the NSS of both the
(FPI+saline) group and the (FPI+etanercept) group
were significantly (P<0.05) higher than those of the
untreated sham-FPI group (10 or 5 vs 0; n=8 for
each) (Figure 1A). However, compared with those of
the (FPI+saline) group, the the NSS values of the (FPI
+etanercept) group (n=8) were significantly (P<0.05)
lower. In contrast, motor function tests showed that
the maximal angles of the (FPI+saline) group were
significantly (P<0.05) lower than those of the sham-
FPI group (60° Vs 30°; n=8 for each) (Figure 1B).
Compared with those of the (FPI+saline) group, the
maximal degrees were significantly (P<0.05) higher in
the (FPI+etanercept) group (30° Vs 45°; n=8 for each)
(Figure 1B).f co-localization of microglia and TNF-α specific marker cells in
er FPI, respectively, (A) a sham operation rat, (B) for a FPI+saline rat
icant increase of the numbers of co-localization of microglia and TNF-α
pared with the sham controls (■) (*P < 0.01). The FPI+etanercept group
croglia and TNF-α specific marker cells compared with the FPI+saline
per group.
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attenuated
TTC staining showed that the (FPI+saline) group had
significantly (P<0.001) larger areas of brain ischemia
than did the sham-FPI group (Figure 1C). (186±26
mm3 vs 21±5 mm3; n=8 for each group). The cerebral
ischemia areas were significantly (P<0.01) smaller in
the FPI+etanercept group than in the FPI+saline group
(104±12 mm3 vs 186±26 mm3; n=8 for each group)
(Figure 1C).
FPI caused the microglial production of TNF-α, which
etanercept attenuated
Immunofluorescence staining revealed that the number of
colocalization of microglia and TNF-α specific markers in
the ischemic cortex (Figure 2), white matter (Figure 3),Figure 6 Etanercept or FPI treatment did not affect the number of co
ischemic cerebral cortical regions. Representative panel staining 72 h aft
a FPI+saline rat and (C) a FPI+etanercept rat. (D) The FPI+saline group (▤)
the number of co-localization of neurons and TNF-α specific marker cells in
group (■) (P>0.05). Each column and bar is the mean±SD of eight rats perand hippocampus (Figure 4) and hypothalamus (Figure 5)
were significantly higher (P<0.01) in the FPI+saline group
than in the sham group, when evaluated 72 h after the
start of FPI. Nevertheless, compared with those of the
saline-treated FPI group, the etanercept-treated FPI rats
had significantly (P<0.01) lower values of the numbers of
co-localization of microglia and TNF-α specific markers
in the ischemic cortex (Figure 2), white mater (Figure 3),
hippocampus (Figure 4), and hypothalamus (Figure 5).
On the other hand, numbers of the co-localization of
TNF-α and neurons specific marker cells (Figure 6A) or
TNF-α and astrocytes specific marker cells (Figure 7) in
the ischemic cortex of the saline-treated or the
etanercept-treated FPI groups were not significantly dif-
ferent (P>0.01) from the sham group when evaluated 72
hours after FPI or sham operation.-localization of neurons and TNF-α specific marker cells in the
er sham operation or FPI, respectively for (A) a sham operation rat, (B)
or the FPI+etanercept group (▩) showed an insignificant change in
the ischemic cortex 72 h after FPI compared with the sham operation
group.
Figure 7 Etanercept or FPI treatment did not affect the number of co-localization of astrocytes and TNF-α specific marker cells in the
ischemic cerebral cortical regions. Representative panel staining 72 h after sham operation or FPI, respectively for (A) a sham operation rat, (B)
a FPI+saline rat (C) a FPI+etanercept rat. (D) The FPI+saline group (▤) or the FPI+etanercept group (▩) showed an insignificant change in the
number of co-localization of astrocytes and TNF-α specific marker cells in the ischemic cortex 72 h after FPI compared with the sham operation
group (■) (P>0.05). Each column and bar is the mean±SD of eight rats per group.
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etanercept attenuated
The cerebral levels of TNF-α were consistently signifi-
cantly (P<0.05) higher for the FPI+saline and the FPI
+etanercept groups than for the sham group 72 h after
FPI or sham operation (Figure 8), but significantly lower
in the FPI+etanercept group than in the FPI+saline
group.
Discussion
The major findings of our present study are: (1)
etanercept injected systemically reduces motor and
neurological deficits caused by FPI by day 3 after FPI;
(2) the increased numbers of the co-localization of
TNF-α and microglia specific marker cells are signifi-
cantly and selectively higher in the ischemic cortex,
white matter, hippocampus, and hypothalamus duringFPI which can be attenuated by etanercept therapy; (3)
overproduction of cerebral TNF-α in the ischemic cortex
caused by FPI can be attenuated by etanercept; (4) by day
3 after FPI, neither the co-localization of TNF-α and
astrocyte specific marker cells nor the TNF-α and neuron
specific marker cells can be seem in the ischemic brain
regions. Our data suggest that systemic administration of
etanercept may improve outcome of FPI by attenuating
the activation of microglial TNF-α in the ischemic brain.
The hypothesis is in part supported by many investiga-
tions. For example, Li and Colleagues [16] has reported
that TNF-α is significantly higher in the lesion boundary
zone in the saline-treated rats by 3 days after FPI. Cere-
bral inflammation in response to trauma, stroke, and
seizure is characterized by the activation of resident
microglia [17-19]. Activated microglia proliferate, change
morphology by assuming an amoeboid shape, increase
Figure 8 Etanercept attenuated TBI-induced increased brain
levels of TNF-α. *The FPI+saline group (▤; n=8) showed a significant
increase in ischemic cortical levels of TNF-α (P<0.01) compared with
the untreated sham-FPI group (■). +The FPI+etanercept group
(▩; n=8) showed a significant decrease in the ischemic cortical levels
of TNF-α (P<0.05) compared with the FPI+saline group (▤; n=8).
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lease cytokines [20,21].
TNF-α transduces death- and survival-signaling
through its cognate receptors TNFR1 and TNFR2 and is
involved in the inflammatory response following TBI
[22-25]. Increases in TNF-α and other cytokines have
been reported in cerebrospinal fluid and plasma samples
in TBI patients [2,26-29]. Several groups [3,5,30-34] have
reported increased TNF-α and other cytokine levels 1 h
post-TBI, and peak levels 4 h post-TBI, after which,
levels returned toward baseline. In Knoblach et al., [31],
a secondary lesser increase at 72 h post-TBI was also
reported. Furthermore, Holmin and Mathiesen [32]
reported persistent elevations 4 days to 3 months after
TBI, and Li et al., [16] found that TNF-α and other cyto-
kines were significantly higher in the lesion boundary
zone in saline-treated TBI rats 3 days post-TBI. In our
rat model, microglial overproduction of TNF-α in se-
veral ischemic brain regions 3 days after TBI was also
reported. In particular, Knoblch et al. [31] reported peak
levels of TNF-α very early after TBI (1–4 hours) with
localization to neurons, whereas our present results
showed the peak levels of TNF-α occurred at 72 hours
and were localized to the microglial cells. Thus, it ap-
pears that the cellular sources of this early elevation of
TNF-α may be time-dependent. However, the most im-
portant point is that this elevated post-TBI TNF-α pro-
duction in brain tissues can be significantly attenuated
by etanercept therapy.
Accumulated evidence shows that TNF-α and its re-
ceptor play an important role in the pathophysiology of
TBI [22,24,25]. In contrast, some evidence suggests that
TNF-α plays a neuroprotective role following TBI
[35,36]. Although TNF-α contributes to neuro-anatomicalplasticity as well as an improvement of locomotor activity
during recovery process [37], present data indicate that
TNF-α is associated with the pathological effects as well
as neurological motor deficits during acute phase after
TBI. In the present study, despite the etanercept treatment
there is still a robust TNF-α release post-injury. However,
etanercept should be given only at acute phase [35,36]. A
greater dose of etanercept administered during recovery
process would not improve outcome and even exacerbate
the pathological effects of TBI.
Etanercept, when administered systemically at the dos-
age approved for its licensed indications (~50 mg/week in
human), would not be expected to achieved therapeutic
levels in the cerebrospinal fluid because of its high mo-
lecular weight [38]. It should be mentioned that the
etanercept doses used in the present set-up are far higher
than the normal subcutaneous dose used for rheumatoid
arthritis. Administration of a dose in humans might result
in significant penetration of etanercept into the cerebro-
spinal fluid; particularly in an experimental setting such as
TBI, in which the blood- cerebrospinal fluid barrier might
be damaged.
The present study focuses mainly the effects of
etanercept on microglial overproduction of TNF-α in the
rat brain effected by TBI. Actually, in addition to TNF-α,
TBI-induced increased levels of both interleukin-1β and
interleukin-6 were all significantly reduced by etanercept
treatment [8]. Additionally, Iba1 stain was chosen as a
marker of activated microglia. Stains for surveillance
microglia would help clarify if etanercept interferes with
microglia activation and/or interferes with chemokines
production and subsequent migration of microglia to the
contused/ischemic areas of the brain. Furthermore, it is
possible that the beneficial effects of etanercept during
TBI are a result of limiting macrophage recruitment in
part [39].
It should be mentioned that in the present study, there
appears to be quite a few instances of Iba1 and TNF-α
labeling that do not coincide and the staining morph-
ology is quite different in some instances (mor elongated
Iba1 staining versus round/amoeboid TNF-α staining).
Furthermore, Iba1 is not a particularly distinguishing
cell-specific marker for microglia in the injured brain as
infiltrating macrophages also express this antigen. In
addition, although our present study showed that the
sham-group displayed no evidence of damage 3 days
post-FPI, Jones et al. [12] did display evidence of damage
one month post-FPI. The discrepancy between our re-
sults and their findings could be due to time difference.
Finally, it should be mentioned that given that the
sham animals in the present study did not receive injec-
tions on any treatment the authors might comment on
the possible confound that the stress associated with the
injections may have had on the TBI group versus sham.
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The present study demonstrates that TBI, in addition to
inducing cerebral contusion and neurological motor def-
icits, cause the microglial overproduction of TNF-α in
the injured cortex, hippocampus, white matter, and
hypothalamus. The TBI-induced neurological motor def-
icits and microglial overproduction of TNF-α can be sig-
nificantly attenuated by the post-TBI application of
etanercept. Our data identify a role for the microglial
production of TNF-α in the outcomes of TBI in rats.
Etanercept may attenuate cerebral contusion and neuro-
logical motor deficits during TBI by inhibiting the acti-
vation of the microglia-TNF-α double positive cells in
the ischemic brain region.
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